Patents by Inventor Junichi Mineno
Junichi Mineno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9422576Abstract: According to the present invention, an AAV vector having a higher titer compared with those of conventional ones can be produced using a cell into which a nucleic acid capable of expressing miRNA is introduced artificially. An AAV vector produced using the cell and a composition containing the viral vector as an active ingredient are very useful as gene transfer means in the studies or clinical practice of gene therapies.Type: GrantFiled: June 26, 2013Date of Patent: August 23, 2016Assignee: TAKARA BIO INC.Inventors: Toshikazu Nishie, Fuyuko Takashima, Tatsuji Enoki, Junichi Mineno
-
Patent number: 9399780Abstract: The present invention provides a method for producing a virus vector, which involves a step of culturing a cell capable of producing the virus vector in a culture medium containing a retinoic acid compound, a histone deacetylase-inhibiting substance and a substance capable of forming a chelate; and a culture medium for use in the production of a virus vector, which is characterized by containing a retinoic acid compound, a histone deacetylase-inhibiting substance and a substance capable of forming a chelate as active ingredients.Type: GrantFiled: March 14, 2013Date of Patent: July 26, 2016Assignee: TAKARA BIO INC.Inventors: Kazuhisa Shinmura, Hirofumi Yoshioka, Hikaru Takakura, Junichi Mineno
-
Publication number: 20160152955Abstract: The present invention provides a method for efficiently manufacturing a non-enveloped virus with high purity without laborious operation by cultivating cells having the ability to produce a non-enveloped virus and bringing the cells and an acidic solution into contact with each other. A non-enveloped virus vector manufactured by the method of the present invention and a composition having the non-enveloped viral vector as an active ingredient are very useful as gene transfer methods in the fields of basic research and clinical application gene therapy.Type: ApplicationFiled: July 10, 2014Publication date: June 2, 2016Applicant: TAKARA BIO INC.Inventors: Shuhei SAKAMOTO, Yasuhiro KAWANO, Katsuyuki DODO, Tatsuji ENOKI, Hirofumi YOSHIOKA, Hikaru TAKAKURA, Junichi MINENO
-
Patent number: 9296807Abstract: Disclosed is a cell which can express a non-natural oligomeric protein, which has, introduced therein, a gene encoding an exogenous polypeptide corresponding to at least one endogenous polypeptide constituting a natural oligomeric protein, and in which the expression of the endogenous polypeptide is inhibited.Type: GrantFiled: May 1, 2015Date of Patent: March 29, 2016Assignees: TAKARA BIO INC., MIE UNIVERSITYInventors: Junichi Mineno, Sachiko Okamoto, Risa Sumioka, Masanari Kitagawa, Hiroshi Shiku, Ikunoshin Kato
-
Publication number: 20160015751Abstract: Disclosed is a method for enhancing the function of a T cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (PD-L1) and/or programmed death-1 ligand 2 (PD-L2) in the T cell. Also disclosed is a function-enhanced T cell which is produced by the function enhancement method. Further disclosed is a therapeutic agent comprising the function-enhanced T cell. The T cell can enhance an immune response to cancer, and is useful in an immunotherapy effective for cancer and the treatment or prevention of infectious diseases and autoimmune diseases.Type: ApplicationFiled: September 30, 2015Publication date: January 21, 2016Inventors: Hiroshi SHIKU, Hiroaki IKEDA, Koichi IWAMURA, Junichi MINENO, Ikunoshin KATO
-
Patent number: 9228206Abstract: Disclosed is a simple and highly efficient method for introducing a gene into a target cell using a retrovirus vector. The method comprises the steps of (a) placing a liquor containing a retrovirus vector having a foreign gene carried thereon into a bag for cell culture on which a retrovirus-binding substance has been immobilized, and incubating the liquor at a temperature lower than 25° C. for 8-48 hours, thereby producing a culture bag having the retrovirus vector bound thereto, (b) adding a target cell to the culture bag that has been produced in step (a) and incubating the culture bag for 8 hours or less, and (c) flipping the culture bag upside down and incubating the culture bag. The gene introduction method is useful particularly in medicine, cell technology, gene technology, and embryologic technology.Type: GrantFiled: August 12, 2014Date of Patent: January 5, 2016Assignee: TAKARA BIO INC.Inventors: Katsuyuki Dodo, Naoki Saito, Hideto Chono, Junichi Mineno
-
Publication number: 20150329872Abstract: The present invention provides an expression cassette comprising (1) an expression regulatory region having a sequence corresponding to a transcriptional activator-binding region and (2) a nucleic acid encoding a transcriptional activator which is capable of binding to the expression regulatory region, wherein the nucleic acid is operably linked to the expression regulatory region; a method for expressing a target product in a mammalian cell, a method for producing a cell expressing a target product, and a method for producing a target product in a mammalian cell using the expression cassette; and a kit comprising the expression cassette.Type: ApplicationFiled: December 10, 2013Publication date: November 19, 2015Applicant: TAKARA BIO INC.Inventors: Katsuyuki DODO, Takahisa TSUKIHARA, Mayurni SHIMOMURA, Koichi INOUE, Hideto CHONO, Junichi MINENO, Masanari KITAGAWA
-
Patent number: 9181525Abstract: Disclosed is a method for enhancing the function of a T cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (PD-L1) and/or programmed death-1 ligand 2 (PD-L2) in the T cell. Also disclosed is a function-enhanced T cell which is produced by the function enhancement method. Further disclosed is a therapeutic agent comprising the function-enhanced T cell. The T cell can enhance an immune response to cancer, and is useful in an immunotherapy effective for cancer and the treatment or prevention of infectious diseases and autoimmune diseases.Type: GrantFiled: March 5, 2010Date of Patent: November 10, 2015Assignees: MIE UNIVERSITY, TAKARA BIO INC.Inventors: Hiroshi Shiku, Hiroaki Ikeda, Koichi Iwamura, Junichi Mineno, Ikunoshin Kato
-
Patent number: 9175308Abstract: Provided are a chimeric antigen receptor comprising an extracellular domain capable of binding to an antigen, a transmembrane domain and at least one intracellular domain, the chimeric antigen receptor being characterized in that an intracellular domain of a glucocorticoid-induced tumor necrosis factor receptor (GITR) is contained as the intracellular domain; a nucleic acid encoding the chimeric antigen receptor; a cell expressing the chimeric antigen receptor; and a method for producing the cell.Type: GrantFiled: October 5, 2012Date of Patent: November 3, 2015Assignees: MIE UNIVERSITY, TAKARA BIO INC.Inventors: Hiroshi Shiku, Yuki Orito, Junichi Mineno, Sachiko Okamoto, Yasunori Amaishi
-
Publication number: 20150291980Abstract: According to the present invention, an AAV vector having a higher titer compared with those of conventional ones can be produced using a cell into which a nucleic acid capable of expressing miRNA is introduced artificially. An AAV vector produced using the cell and a composition containing the viral vector as an active ingredient are very useful as gene transfer means in the studies or clinical practice of gene therapies.Type: ApplicationFiled: June 26, 2013Publication date: October 15, 2015Applicant: TAKARA BIO INC.Inventors: Toshikazu Nishie, Fuyuko Takashima, Tatsuji Enoki, Junichi Mineno
-
Patent number: 9144603Abstract: Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject.Type: GrantFiled: October 15, 2013Date of Patent: September 29, 2015Assignees: MIE UNIVERSITY, TAKARA BIO INC.Inventors: Hiroshi Shiku, Hiroaki Ikeda, Jun Mitsui, Yuki Takenaka, Junichi Mineno, Ikunoshin Kato
-
Publication number: 20150232530Abstract: Disclosed is a cell which can express a non-natural oligomeric protein, which has, introduced therein, a gene encoding an exogenous polypeptide corresponding to at least one endogenous polypeptide constituting a natural oligomeric protein, and in which the expression of the endogenous polypeptide is inhibited.Type: ApplicationFiled: May 1, 2015Publication date: August 20, 2015Inventors: Junichi MINENO, Sachiko OKAMOTO, Risa SUMIOKA, Masanari KITAGAWA, Hiroshi SHIKU, Ikunoshin KATO
-
Patent number: 9102943Abstract: The present invention provides a method for producing a virus vector, which comprises a step wherein cells that are capable of producing a virus vector are cultured in a culture medium that contains, as active components, a retinoic acid and a histone deacetylase inhibiting substance; and a culture medium for the production of a virus vector, which is characterized by containing, as active components, a retinoic acid and a histone deacetylase inhibiting substance.Type: GrantFiled: October 4, 2011Date of Patent: August 11, 2015Assignee: TAKARA BIO INC.Inventors: Kazuhisa Shinmura, Yoshinori Katayama, Kensuke Sakai, Toshihiro Shodai, Hirofumi Yoshioka, Junichi Mineno
-
Patent number: 9057056Abstract: The N-acetylglucosaminyltransferase III activity is enhanced in a cell carrying retrovirus-origin gag-pol gene and env gene. By constructing a retrovirus vector with the use of the above cell, a retrovirus vector having a modified sugar chain structure can be obtained. The retrovirus vector constructed by this method shows a high infection efficiency particularly in the presence of a functional substance.Type: GrantFiled: September 28, 2005Date of Patent: June 16, 2015Assignee: TAKARA BIO INC.Inventors: Hideto Chono, Hiromi Okuyama, Tomoe Egashira, Nobuto Koyama, Junichi Mineno, Ikunoshin Kato
-
Patent number: 9051391Abstract: Disclosed is a cell which can express a non-natural oligomeric protein, which has, introduced therein, a gene encoding an exogenous polypeptide corresponding to at least one endogenous polypeptide constituting a natural oligomeric protein, and in which the expression of the endogenous polypeptide is inhibited.Type: GrantFiled: June 10, 2008Date of Patent: June 9, 2015Assignees: TAKARA BIO INC., MIE UNIVERSITYInventors: Junichi Mineno, Sachiko Okamoto, Risa Sumioka, Masanari Kitagawa, Hiroshi Shiku, Ikunoshin Kato
-
Publication number: 20150079050Abstract: The present invention provides a method for producing a virus vector, which involves a step of culturing a cell capable of producing the virus vector in a culture medium containing a retinoic acid compound, a histone deacetylase-inhibiting substance and a substance capable of forming a chelate; and a culture medium for use in the production of a virus vector, which is characterized by containing a retinoic acid compound, a histone deacetylase-inhibiting substance and a substance capable of forming a chelate as active ingredients.Type: ApplicationFiled: March 14, 2013Publication date: March 19, 2015Inventors: Kazuhisa Shinmura, Hirofumi Yoshioka, Hikaru Takakura, Junichi Mineno
-
Publication number: 20150037300Abstract: A nucleic acid comprising a transcription regulation sequence whose transcription is induced by a trans-acting factor of a human immunodeficiency virus and a gene encoding a polypeptide having an endoribonuclease activity specific to single-stranded RNA, wherein the gene is located in such a position that the expression of the gene can be regulated by the transcription regulation sequence; a method for production of a cell showing an inhibited replication of a human immunodeficiency virus therein, the method comprising the step of introducing the nucleic acid into a cell; and a method for treatment or prevention of a human immunodeficiency virus infection.Type: ApplicationFiled: October 16, 2014Publication date: February 5, 2015Inventors: Hideto CHONO, Kazuya Matsumoto, Junichi Mineno, Ikunoshin Kato
-
Publication number: 20140349404Abstract: Disclosed is a simple and highly efficient method for introducing a gene into a target cell using a retrovirus vector. The method comprises the steps of (a) placing a liquor containing a retrovirus vector having a foreign gene carried thereon into a bag for cell culture on which a retrovirus-binding substance has been immobilized, and incubating the liquor at a temperature lower than 25° C. for 8-48 hours, thereby producing a culture bag having the retrovirus vector bound thereto, (b) adding a target cell to the culture bag that has been produced in step (a) and incubating the culture bag for 8 hours or less, and (c) flipping the culture bag upside down and incubating the culture bag. The gene introduction method is useful particularly in medicine, cell technology, gene technology, and embryologic technology.Type: ApplicationFiled: August 12, 2014Publication date: November 27, 2014Inventors: Katsuyuki DODO, Naoki SAITO, Hideto CHONO, Junichi MINENO
-
Patent number: 8889844Abstract: A nucleic acid comprising a transcription regulation sequence whose transcription is induced by a trans-acting factor of a human immunodeficiency virus and a gene encoding a polypeptide having an endoribonuclease activity specific to single-stranded RNA, wherein the gene is located in such a position that the expression of the gene can be regulated by the transcription regulation sequence; a method for production of a cell showing an inhibited replication of a human immunodeficiency virus therein, the method comprising the step of introducing the nucleic acid into a cell; and a method for treatment or prevention of a human immunodeficiency virus infection.Type: GrantFiled: August 10, 2006Date of Patent: November 18, 2014Assignee: Takara Bio Inc.Inventors: Hideto Chono, Kazuya Matsumoto, Junichi Mineno, Ikunoshin Kato
-
Patent number: 8852915Abstract: A method of retrovirus storage, characterized in that a retrovirus is sustained in the presence of a substance with retrovirus binding activity immobilized on a solid phase. Further, there is provided a retrovirus composition characterized in that a retrovirus in the form of binding to a substance with retrovirus binding activity is sealed in a container holding a solid phase having the substance with retrovirus binding activity immobilized thereon.Type: GrantFiled: October 12, 2012Date of Patent: October 7, 2014Assignee: Takara Bio Inc.Inventors: Hideto Chono, Yasushi Katayama, Hiromi Okuyama, Junichi Mineno, Kiyozo Asada, Ikunoshin Kato